The ASPIRE trial: Once-daily TMC435 in treatment-experienced patients with genotype 1 HCV infection who have failed previous PegIFN/RBV treatment

Authors
Category Primary study
ConferenceHepatology International
Year 2012
This article has no abstract
Epistemonikos ID: 03745bbc51d3f0f89b4e713131cd54f940785978
First added on: Apr 30, 2026